The Aurora Kinase B Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Aurora Kinase B Market?
The market size of the aurora kinase b sector has seen significant growth recently. The market size is projected to rise from $1.14 billion in 2024 to $1.27 billion in 2025, representing a compound annual growth rate (CAGR) of 12.1%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Aurora Kinase B Industry?
The market size for the atrial flutter sector is predicted to reach $40.43 billion in 2029, growing at a compound annual growth rate (CAGR) of 15.2%.
Download Your Free Sample of the 2025 Aurora Kinase B Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Aurora Kinase B Market?
The key drivers in the aurora kinase b market are:
• Rising investments in innovative cancer treatment
• Growing incidence of drug-resistant cancers
• Increasing focus on research and development
• Rising demand for combination therapies
Global Market Segmentation: Identifying Major Aurora Kinase B Industry Segments
The aurora kinase b market covered in this report is segmented –
1) By Type: AZD-2811, CS-2164, Danusertib, Ilorasertib, NMI-900, Other Types
2) By Application: Anaplastic Large Cell Lymphoma, Kidney Cancer, Lung Cancer, Prostate Cancer, Other Applications
3) By End-User: Hospitals, Research Institutes, Diagnostic Laboratories, Other End-Users
Subsegments:
1) By AZD-2811: Phase I Clinical Trials AZD-2811, Preclinical Development of AZD-2811, AZD-2811 in Combination Therapy, Targeted Cancer Treatment with AZD-2811
2) By CS-2164: Phase II Clinical Trials CS-2164, Preclinical Development of CS-2164, CS-2164 in Targeted Cancer Therapy, CS-2164 Combination Therapy in Clinical Studies
3) By Danusertib: Phase III Clinical Trials Danusertib, Danusertib for Hematological Malignancies, Danusertib for Solid Tumors, Combination Therapy with Danusertib
4) By Ilorasertib: Preclinical Development of Ilorasertib, Ilorasertib in Solid Tumor Treatment, Phase I and II Clinical Trials of Ilorasertib, Ilorasertib in Combination with Chemotherapies
5) By NMI-900: NMI-900 in Early-Stage Clinical Trials, NMI-900 for Targeted Cancer Therapy, Preclinical Studies of NMI-900, NMI-900 Combination Therapy Trials
6) By Other Types: Other Aurora Kinase B Inhibitors in Development, Novel Targeted Aurora Kinase B Drugs, Combination Therapies Involving Aurora Kinase B Inhibitors, Investigational Aurora Kinase B Inhibitors in Oncology
Pre-order the 2025 Aurora Kinase B Global Market Report for Fast Delivery & Comprehensive Insights!
What are the emerging Trends Shaping the Future of the Aurora Kinase B Market?
The key trends in the aurora kinase b market are:
• Technological advancements are a key trend reshaping the market.
• Precision medicine is emerging as a significant trend.
• There is a rising trend of employing data analytics in this field.
• Novel therapies are becoming increasingly prevalent in the market.
Who Are the Top Competitors & Leading Players in the Aurora Kinase B Market?
Major players in the aurora kinase b market are:
• Pfizer Inc.
• Johnson & Johnson
• Siemens AG
• Bristol-Myers Squibb Company
• Abbott Laboratories
• Novartis AG
• Medtronic PLC
• Boehringer Ingelheim GmbH
• Stryker Corporation
• GE HealthCare Technologies Inc.
• Boston Scientific Corporation
• Astellas Pharma Inc.
• Zoll Medical Corporation
• St. Jude Medical Inc.
• Biotronik SE & Co.
• iRhythm Technologies Inc.
• AtriCure Inc.
• Valley Health System Inc.
• Adagio Medical Inc.
• Acutus Medical Inc.
Regional Dominance: Which Area Leads the Global Template Market?
North America was the largest region in the aurora kinase B market in 2024
